2026 Global: Acute Migraine Treatments Market -Competitive Review (2032) report
Description
The 2026 Global: Acute Migraine Treatments Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for acute migraine treatments market by geography and historical trend. The scope of the report extends to sizing of the acute migraine treatments market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The acute migraine treatments market features ten major companies driving innovation through CGRP inhibitors, gepants, triptans, and novel formulations like nasal powders and autoinjectors. Leading players include Amgen, Eli Lilly & Company, Teva Pharmaceutical Industries, Pfizer Inc., and AbbVie, which dominate with products such as Aimovig, Emgality, Ajovy, Nurtec ODT, and Ubrelvy. Novartis, AstraZeneca, Merck & Co., Johnson & Johnson, and GlaxoSmithKline round out the top tier, contributing therapies like undisclosed CGRP targets, preventive options, and established triptans that address both acute attacks and prevention. These firms control significant market share amid projections of growth from USD 3.85 billion in 2025 to USD 10.08 billion by 2034, fueled by FDA approvals and pipeline advancements.
Amgen and Eli Lilly lead with blockbuster CGRP monoclonal antibodies, including Aimovig (erenumab) and Emgality (galcanezumab), which reduce migraine days by blocking peptide pathways, alongside Lilly's Reyvow (lasmiditan) for acute relief without vasoconstriction. Teva's Ajovy (fremanezumab) gained traction with positive Phase 3 data in China in January 2025, while Pfizer's Nurtec ODT (rimegepant) secured Korean approval in 2025 for oral CGRP antagonism, offering dual acute-preventive use. AbbVie's Ubrelvy (ubrogepant) pioneered oral gepants in 2019, expanding to symptom relief like photophobia, and Novartis bolsters the field with preventive biologics. Recent entrants like Axsome Therapeutics' Symbravo (approved January 2025) challenge incumbents with multi-mechanistic meloxicam-rizatriptan combos for rapid, sustained pain freedom.
Emerging dynamics see AstraZeneca, Merck, Johnson & Johnson, and GlaxoSmithKline investing in gepants, ditans, and devices amid competition from Biohaven (rIVZ, vazegepant) and Lundbeck acquisitions. Pipeline highlights include Amneal's Brekiya autoinjector (FDA-approved May 2025) for self-administered dihydroergotamine and Satsuma's Atzumi nasal powder (April 2025), reshaping delivery for non-responders to triptans, which hold 48.9% revenue share. These majors adapt via telemedicine integrations and AI tracking, targeting hospital pharmacies (42.35% share) while smaller players like Impel and Zosano push nasal DHE and microneedle patches. Overall, CGRP dominance persists, but multi-modal therapies promise personalized acute care through 2034.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for acute migraine treatments market by geography and historical trend. The scope of the report extends to sizing of the acute migraine treatments market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The acute migraine treatments market features ten major companies driving innovation through CGRP inhibitors, gepants, triptans, and novel formulations like nasal powders and autoinjectors. Leading players include Amgen, Eli Lilly & Company, Teva Pharmaceutical Industries, Pfizer Inc., and AbbVie, which dominate with products such as Aimovig, Emgality, Ajovy, Nurtec ODT, and Ubrelvy. Novartis, AstraZeneca, Merck & Co., Johnson & Johnson, and GlaxoSmithKline round out the top tier, contributing therapies like undisclosed CGRP targets, preventive options, and established triptans that address both acute attacks and prevention. These firms control significant market share amid projections of growth from USD 3.85 billion in 2025 to USD 10.08 billion by 2034, fueled by FDA approvals and pipeline advancements.
Amgen and Eli Lilly lead with blockbuster CGRP monoclonal antibodies, including Aimovig (erenumab) and Emgality (galcanezumab), which reduce migraine days by blocking peptide pathways, alongside Lilly's Reyvow (lasmiditan) for acute relief without vasoconstriction. Teva's Ajovy (fremanezumab) gained traction with positive Phase 3 data in China in January 2025, while Pfizer's Nurtec ODT (rimegepant) secured Korean approval in 2025 for oral CGRP antagonism, offering dual acute-preventive use. AbbVie's Ubrelvy (ubrogepant) pioneered oral gepants in 2019, expanding to symptom relief like photophobia, and Novartis bolsters the field with preventive biologics. Recent entrants like Axsome Therapeutics' Symbravo (approved January 2025) challenge incumbents with multi-mechanistic meloxicam-rizatriptan combos for rapid, sustained pain freedom.
Emerging dynamics see AstraZeneca, Merck, Johnson & Johnson, and GlaxoSmithKline investing in gepants, ditans, and devices amid competition from Biohaven (rIVZ, vazegepant) and Lundbeck acquisitions. Pipeline highlights include Amneal's Brekiya autoinjector (FDA-approved May 2025) for self-administered dihydroergotamine and Satsuma's Atzumi nasal powder (April 2025), reshaping delivery for non-responders to triptans, which hold 48.9% revenue share. These majors adapt via telemedicine integrations and AI tracking, targeting hospital pharmacies (42.35% share) while smaller players like Impel and Zosano push nasal DHE and microneedle patches. Overall, CGRP dominance persists, but multi-modal therapies promise personalized acute care through 2034.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.